abstract |
The present invention relates to a marker composition for predicting anticancer drug resistance comprising one or more genes selected from the group consisting of CLDN7, CRIP1, ERSP1 and TYMP, a marker for predicting anticancer drug resistance, Compositions and kits, and methods for providing information on the diagnosis of resistance to anticancer drugs through expression analysis of the genes. The CLDN7, CRIP1, ERSP1 and TYMP genes of the present invention are genes whose expression is markedly reduced in anticancer-resistant cell lines, and the resistance to the anticancer drug can be effectively predicted by using the genes. In addition, by using the marker of the present invention, efficient chemotherapy can be performed by selecting patients showing an effect on the anticancer drug, and the drug can be utilized to develop drugs that target the gene and enhance the sensitivity of the anticancer drug |